Prof Joseph Trapani
Director, Centre for Cancer Immunotherapy
The Sir Peter MacCallum Department of Oncology
443 Scholarly works
35 Projects
HIGHLIGHTS
2026
Journal article
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition.
DOI: 10.1126/sciadv.ady02962026
Journal article
Differential perforin sensitivity drives lineage-dependent resistance to CAR T-cell killing in blood cancer cell lines
DOI: 10.1182/bloodadvances.20260198812026
Journal article
Pharmacological inhibition of perforin dampens CD8 T cell-mediated beta cell destruction in autoimmune diabetes in mice
DOI: 10.1007/s00125-026-06773-82026
Journal article
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunity
DOI: 10.1016/j.celrep.2025.1166652020
Research grants (ARC, NHMRC, MRFF)
Immunobiology of Cancer and New Cancer Treatments
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Immunobiology and Immunotherapy of Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
Hypoxia and IL-15 Cooperate to Induce Perforin Expression by CD8 T Cells and Promote Damage to the Skin in Murine Cutaneous Leishmaniasis
DOI: 10.1016/j.jid.2025.04.0292025
Conference Proceedings
DLBCL tumor microenvironment archetype and CD4 T cell conversion to cytotoxic cells are required for response to glofitamab
DOI: 10.1182/blood-2025-5572025
Journal article
Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models
DOI: 10.1126/scitranslmed.adk06272025
Journal article
MON-312 Lewis Y Antigen as a Novel Target for CAR (Chimeric Antigen Receptor) T-cell Therapy in Patients with Neuroendocrine Prostate Cancer
DOI: 10.1210/jendso/bvaf149.24122025
Journal article
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation
DOI: 10.1016/j.molcel.2025.08.0012025
Journal article
197 | CD4 T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP
DOI: 10.1002/hon.70094_197
RECENT PROJECTS
2024
Research grants (other domestic)
How to Curb Cytokine Release Syndrome in Patients Undergoing Immunotherapy
2022
Research grants (ARC, NHMRC, MRFF)
mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13